Vinorelbine with or without Trastuzumab in Metastatic Breast Cancer: A Retrospective Single Institution Series

Table 2

Clinical response rates of patients with metastatic breast cancer treated with vinorelbine (with or without trastuzumab) either as 1st or as later line of treatment.

	1st line; 𝑛=54 (%)	95% CI (%)	2nd or later line; 𝑛=16 (%)	95% CI
CR	1 (1.9%)	0–10.7	0	0–22.7
PR	23 (42.6%)	30.3–55.9	2 (12.5%)	2.2–37.3
SD	12 (22.2%)	13.0–35.1	6 (37.5%)	18.4–61.5
PD	18 (33.3%)	22.2–46.7	8 (50%)	28.0–72.0

CR: complete response, PR: partial response, SD: stable disease, PD: progressive disease, and 95% CI: 95% confidence interval.